COMMUNIQUÉS West-GlobeNewswire

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
07/04/2026
CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, [...]
Valitor Announces Oral Presentation at the Upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
07/04/2026
BERKELEY, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced the company will present new preclinical data highlighting the [...]
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
07/04/2026
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
07/04/2026
Joint Release Expands 20/20 BioLabs’ Testing Solutions Across Evexia’s Network of ~40,000 Functional and Integrative Medicine Practitioners Marks a Commercial Expansion Milestone for OneTest for Cancer Across Evexia’s [...]
Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® Utilization
07/04/2026
Results to be featured at Functional Diabetic Limb Salvage, Society of Advanced Wound Care and American Burn Association Conferences in April PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences [...]
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
07/04/2026
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations totaling $2 million to multiple patient assistance foundations [...]
Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
07/04/2026
Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026 The trial has already yielded encouraging one- and two-year data including a 75% Objective [...]
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
07/04/2026
New product offerings and educational initiative, Ready to Rescue, aim to increase access and adoption of NARCAN® Nasal Spray to empower communities to save a life in an opioid overdose emergency GAITHERSBURG, Md., [...]
GATC Health and UC Irvine Announce Landmark PNAS Publication Validating AI-Platform for Opioid Use Disorder Treatment
07/04/2026
IRVINE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, and researchers from the University of [...]
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
07/04/2026
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial [...]
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
07/04/2026
PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president [...]
NTG Nordic Transport Group A/S - Q1 2026 Conference Call
07/04/2026
NTG Nordic Transport Group A/S – Q1 2026 Conference Call We expect to release the Q1 2026 interim results of NTG Nordic Transport Group on the evening of May 5, 2026. A webcast and conference call will be held in the [...]
Virbac : Déclaration d'actions et de droits de votes 03/2026
07/04/2026
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Transactions in connection with share buy-back program
07/04/2026
Company announcement no. 9 - 26 07 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Virbac : Declaration of the number of shares and voting rights 03/2026
07/04/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
07/04/2026
COPENHAGEN, Denmark, April 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to [...]
Oculis to Participate in Upcoming Investor Conferences
07/04/2026
ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
SonoNeu exits stealth as key part of US Government-funded research program worth up to $41.3m to advance sonogenetics into clinic
07/04/2026
Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged’ with special proteins SonoNeu is part of a collaborative project, also [...]
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
07/04/2026
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma [...]

Pages